Halozyme Therapeutics, Inc., San Diego, CA
Song Wang , Nicholas Willumsen , Cecilie Bager , Morten A Karsdal , Dimitrios Chondros , Darin Taverna
Background: Hyaluronan (HA) and collagens are major constituents of the ECM. HA accumulation in the tumor microenvironment may result in elevated interstitial fluid pressure, vascular compression, and reduced drug delivery and immune cell access. PEGPH20 degrades HA, increasing tumoral access for therapeutics and immune cells. Liquid biopsies reflecting ECM remodeling may provide a non-invasive approach to identify pts most likely to benefit from PEGPH20 therapy. Methods: Peptide markers of ECM remodeling (C3M, PRO-C3, PRO-C6, and VCANM) were measured using baseline plasma samples from Stage 1 (n=94) and Stage 2 (n=95) of HALO-109-202 (NCT01453153), a Phase 2, open-label, randomized study of PEGPH20 + A + G (PAG) vs AG in previously untreated pts with Stage IV PDAC. Univariate and ratio analyses were conducted to correlate biomarker levels with survival outcomes (PFS, OS). Results: The ratio of C3M (MMP degradation fragment of type-III collagen) vs PRO-C3 (N-terminal pro-peptide of type-III collagen) predicted for PFS benefit in PEGPH20-treated pts in Stage 1. The predictive value of this ratio for PFS and OS of PEGPH20-treated pts was further validated in Stage 2. Conclusions: This supports development of a liquid biopsy-based companion diagnostic for selecting pts that may benefit from PEGPH20.
Measurement cut-off | PFS | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Median (mths) | Log-rank, P | HR (95% CI) | ||||||||
AG | PAG | |||||||||
Stage 1 (Discovery cohort) | C3M/PRO-C3 ratio (0.550, 50th percentile) | Ratio-high pts (≥0.550) | 5.3 | 8.0 | 0.026 | 0.40 (0.17–0.92) | ||||
Ratio-low pts (<0.550) | 5.2 | 3.0 | 0.810 | 1.09 (0.55–2.18) | ||||||
Measurement cut-off | PFS | OS | ||||||||
Median (mths) | Log-rank, P | HR (95% CI) | Median (mths) | Log-rank, P | HR (95% CI) | |||||
AG | PAG | AG | PAG | |||||||
Stage 2 (Validation Cohort) | C3M/PRO-C3 ratio (0.550, stage-1 cut-off) | Ratio-high pts (≥0.550) | 3.4 | 8.8 | 0.039 | 0.46 (0.21–0.99) | 8.5 | 13.8 | 0.006 | 0.35 (0.16–0.77) |
Ratio-low pts (<0.550) | 5.8 | 5.3 | 0.560 | 1.30 (0.54–3.16) | 9.0 | 7.9 | 0.523 | 0.80 (0.41–1.57) |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2020 Gastrointestinal Cancers Symposium
First Author: Margaret A. Tempero
2019 Gastrointestinal Cancers Symposium
First Author: Darin Taverna
2021 ASCO Annual Meeting
First Author: Daniel John Renouf
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Zev A. Wainberg